Evotec and venture capital consortium form "Breakpoint Therapeutics GmbH"
Early stage funding amounting to € 30 m
09-Jul-2019 -
Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. Breakpoint ...
cancer therapy
DNA damage response
DNA repair
+2